Shawn Cross's most recent trade in Cyclo Therapeutics Inc - Ordinary Shares - Class A was a trade of 28,597 Common Stock done . Disclosure was reported to the exchange on Feb. 27, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Cyclo Therapeutics Inc - O... | Shawn M. Cross | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Feb 2025 | 28,597 | 136,346 | - | 0 | Common Stock | |
| Cyclo Therapeutics Inc - O... | Shawn M. Cross | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Nov 2024 | 17,228 | 107,749 | - | 0 | Common Stock | |
| Pacira BioSciences Inc | Shawn M. Cross | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Nov 2024 | 200,000 | 200,000 | - | - | Stock Option (Right to Buy) | |
| Pacira BioSciences Inc | Shawn M. Cross | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Nov 2024 | 75,000 | 75,000 (0%) | 0% | 0 | Common Stock | |
| Cyclo Therapeutics Inc - O... | Shawn Cross | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Aug 2024 | 9,028 | 90,521 | - | 0 | Common Stock | |
| Cyclo Therapeutics Inc - O... | Shawn Cross | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jun 2024 | 15,562 | 15,562 | - | - | Stock Option (Right to Buy) | |
| Cyclo Therapeutics Inc - O... | Shawn Cross | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jun 2024 | 8,887 | 81,493 | - | 0 | Common Stock | |
| Applied Molecular Transpor... | Shawn Cross | Director, CEO & Chair of the Board | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Dec 2023 | 668,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Applied Molecular Transpor... | Shawn Cross | Director, CEO & Chair of the Board | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Dec 2023 | 545,499 | 0 | - | - | Common Stock | |
| Applied Molecular Transpor... | Cross Shawn | Director, CEO & Chair of the Board | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Dec 2023 | 300,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Applied Molecular Transpor... | Shawn Cross | Director, CEO & Chair of the Board | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Dec 2023 | 94,500 | 0 | - | - | Stock Option (Right to Buy) | |
| Applied Molecular Transpor... | Cross Shawn | Director, CEO & Chair of the Board | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Dec 2023 | 84,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Applied Molecular Transpor... | Shawn Cross | Director, CEO & Chair of the Board | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Dec 2023 | 63,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Applied Molecular Transpor... | Shawn Cross | Director, CEO & Chair of the Board | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Mar 2023 | 668,000 | 668,000 | - | - | Stock Option (Right to Buy) | |
| Applied Molecular Transpor... | Shawn Cross | President & COO | Sale of securities on an exchange or to another person at price $ 0.50 per share. | 01 Mar 2023 | 934 | 60,156 | - | 0.5 | 467 | Common Stock |
| Applied Molecular Transpor... | Shawn Cross | President & COO | Sale of securities on an exchange or to another person at price $ 1.05 per share. | 02 Dec 2022 | 3,893 | 61,090 | - | 1.1 | 4,088 | Common Stock |
| Applied Molecular Transpor... | Shawn Cross | President & COO | Sale of securities on an exchange or to another person at price $ 1.42 per share. | 01 Sep 2022 | 468 | 65,399 | - | 1.4 | 665 | Common Stock |
| Applied Molecular Transpor... | Shawn Cross | President & COO | Sale of securities on an exchange or to another person at price $ 1.42 per share. | 01 Sep 2022 | 416 | 64,983 | - | 1.4 | 591 | Common Stock |
| Applied Molecular Transpor... | Shawn Cross | President & COO | Sale of securities on an exchange or to another person at price $ 3.04 per share. | 01 Jun 2022 | 2,166 | 65,867 | - | 3.0 | 6,590 | Common Stock |
| Applied Molecular Transpor... | Shawn Cross | President & COO | Sale of securities on an exchange or to another person at price $ 2.97 per share. | 01 Jun 2022 | 1,767 | 67,983 | - | 3.0 | 5,244 | Common Stock |
| Applied Molecular Transpor... | Shawn Cross | President & COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 May 2022 | 84,000 | 84,000 | - | - | Stock Option (Right to Buy) | |
| Applied Molecular Transpor... | Shawn Cross | President & COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 May 2022 | 18,000 | 69,750 | - | 0 | Common Stock | |
| Applied Molecular Transpor... | Shawn Cross | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2022 | 94,500 | 94,500 | - | - | Stock Option (Right to Buy) | |
| Applied Molecular Transpor... | Shawn Cross | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2022 | 20,250 | 51,750 | - | 0 | Common Stock | |
| Applied Molecular Transpor... | Shawn Cross | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Aug 2021 | 9,700 | 300,000 | - | - | Stock Option (Right to Buy) | |
| Applied Molecular Transpor... | Shawn Cross | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 30.12 per share. | 19 Aug 2021 | 9,700 | 0 | - | 30.1 | 292,190 | Common Stock |
| Applied Molecular Transpor... | Shawn Cross | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.61 per share. | 19 Aug 2021 | 9,700 | 9,700 | - | 4.6 | 44,717 | Common Stock |
| Applied Molecular Transpor... | Shawn Cross | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 30.01 per share. | 19 Aug 2021 | 300 | 0 | - | 30.0 | 9,003 | Common Stock |
| Applied Molecular Transpor... | Shawn Cross | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Aug 2021 | 300 | 309,700 | - | - | Stock Option (Right to Buy) | |
| Applied Molecular Transpor... | Shawn Cross | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.61 per share. | 19 Aug 2021 | 300 | 300 | - | 4.6 | 1,383 | Common Stock |
| Applied Molecular Transpor... | Shawn Cross | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2021 | 63,000 | 63,000 | - | - | Stock Option (Right to Buy) |